<DOC>
	<DOC>NCT02598960</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability pharmacokinetics, pharmacodynamics, immunogenicity and preliminary anti-tumor activity of BMS-986156 when administered alone and in combination with nivolumab in subjects with advanced solid tumors.</brief_summary>
	<brief_title>A Study of BMS-986156 Given Alone and in Combination With Nivolumab in Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com For Dose Escalation: Subjects with any previously treated advanced (metastatic or refractory) solid tumor For Cohort Expansion: Subjects must have a previously treated advanced solid tumor to be eligible Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Willing and able to provide pretreatment and ontreatment fresh tumor biopsy Women of childbearing potential and men must use an acceptable method of contraception during treatment and for 23 weeks after treatment for women and 31 weeks for men Known central nervous system metastases or central nervous system as the only source of disease Other concomitant malignancies (with some exceptions per protocol) Active, known or suspected autoimmune disease Uncontrolled or significant cardiovascular disease History of active or chronic hepatitis (e.g. Hep B or C) Impaired liver or bone marrow function Major surgery less than 1 month before start of the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>